Video Experimental Relacionado
Updated: Jul 8, 2026
12:24
Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart
Published on: September 28, 2016
La calcineurina juega un papel crítico en la hipertrofia cardíaca inducida por sobrecarga de presión inducida por la
M Shimoyama1, D Hayashi, E Takimoto
1Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Circulation
|December 14, 1999
Resumen
La activación de la calcineurina impulsa la hipertrofia cardíaca en respuesta a una sobrecarga de presión. La inhibición de la calcineurina con FK506 previene esta hipertrofia, lo que sugiere un papel clave para esta vía de señalización en la adaptación del corazón.
Área de la Ciencia:
- Cardiología Cardiología.
- Biología Molecular Biología Molecular
- La bioquímica es la bioquímica.
Sus antecedentes:
- La hipertrofia cardíaca es una respuesta adaptativa a la sobrecarga hemodinámica.
- Los mecanismos precisos por los cuales la carga mecánica induce la hipertrofia cardíaca no se comprenden completamente.
- Los hallazgos recientes sugieren que la calcineurina, una fosfatasa dependiente del calcio, media la hipertrofia cardíaca.
Objetivo del estudio:
- Para investigar el papel de la calcineurina en la hipertrofia cardíaca inducida por sobrecarga de presión.
- Para determinar si la activación de la calcineurina es un factor crítico en el desarrollo de la hipertrofia cardíaca.
Principales métodos:
- Inducir sobrecarga de presión en ratas a través de la constricción de la aorta abdominal.
- Medición de la actividad de la calcineurina en el tejido cardíaco.
- La administración de FK506, un inhibidor de la calcineurina, para evaluar sus efectos.
- Evaluar la hipertrofia cardíaca, la fibrosis y los cambios en la expresión génica.
Principales resultados:
- La sobrecarga de presión aumentó la actividad de la calcineurina e indujo hipertrofia cardíaca y reprogramación genética.
- El tratamiento con FK506 inhibió la activación de la calcineurina y evitó la hipertrofia y la fibrosis cardíacas.
- FK506 no alteró los parámetros hemodinámicos.
- La expresión inducida por la carga de la respuesta temprana inmediata y los genes fetales fue suprimida por FK506.
Conclusiones:
- La vía de señalización de la calcineurina es fundamental en la hipertrofia cardíaca inducida por la carga.
- La orientación a la calcineurina puede ofrecer una nueva estrategia farmacológica para prevenir la hipertrofia cardíaca.
Videos de Conceptos Relacionados
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...